



UNIVERSITY
OF MEDICINE
AND HEALTH
SCIENCES

Royal College of Surgeons in Ireland

repository@rcsi.com

Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma

AUTHOR(S)

Jarlath Bolger, Jonathan Allen, Nikolina Radulovich, Christine Ng, Mathieu Derouet, Premalatha Shathasivam, Gavin W Wilson, Ming-Sound Tsao, Elena Elimova, Gail E Darling, Jonathan C Yeung

CITATION

Bolger, Jarlath; Allen, Jonathan; Radulovich, Nikolina; Ng, Christine; Derouet, Mathieu; Shathasivam, Premalatha; et al. (2024). Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma. Royal College of Surgeons in Ireland. Journal contribution.
<https://hdl.handle.net/10779/rcsi.25305304.v1>

HANDLE

[10779/rcsi.25305304.v1](https://hdl.handle.net/10779/rcsi.25305304.v1)

LICENCE

CC BY-NC-SA 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/journal_contribution/Patient-derived_organoids_for_prediction_of_treatment_response_in_oesophageal_adenocarcinoma/25305304/1




Figure 2: A) Boxplot demonstrating differences in mean IC50 for platinum based chemotherapy between 'responder' and 'non-responder' subsets, y-axis shows IC50. B) Boxplot demonstrating differences in mean IC50 for taxane chemotherapy between 'responder' and 'non-responder' subsets, y-axis shows IC50. C i and ii) IC50 and EC50 of organoids treated with irinotecan, split into 'responders' and 'non-responders' based on a 4.4-fold difference in mean IC50 ($n=18$). IC50 and EC50 concentrations on y-axis are μM concentration. 4 'responders' had TRG3 following CROSS, and 1 'non-responder' had TRG1 following CROSS. D i and ii) IC50 and EC50 of organoids treated with epirubicin split into 'responders' and 'non-responders' based on a 3.1-fold difference in mean IC50 ($n=13$). IC50 and EC50 concentrations on y-axis are μM concentration. 2 'responders' had TRG3 following neoadjuvant therapy (1 CROSS and 1 FLOT) and 2 'non-responder' had TRG1 following CROSS.